Fibrinogen and fibrin clot structure in diabetes

Herz

Volumn 29, Issue 5, 2004, Pages 470-479

  Dunn, Emma J ^c   Ariëns, Robert A S ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c NONE

Author keywords

Clot; Diabetes; Fibrinogen; Glycation; Lysis

Indexed keywords

ADULT; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS LINKING; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FIBRIN CLOT; FIBRINOGEN METABOLISM; GLYCATION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; REVIEW; RISK FACTOR; THROMBOSIS; TISSUE DISTRIBUTION;

ANIMALS; BLOOD COAGULATION; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FIBRIN; FIBRINOGEN; HUMANS; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION;

EID: 4444252278     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-004-2607-z     Document Type: Review

References (118)

1. Palumbo P, Elveback L, Chu C, et al. Diabetes mellitus: incidence prevalence, survivorship, and causes of death in Rochester, Minnesota. Diabetes 1976;25:566-73.
2. Wingard D, Barrett-Connor E. Heart disease and diabetes. In: Harris M,ed. Diabetes in America, 2nd edn. Bethesda: National Institutes of Health, 1995:429-48.
3. Kannel W, McCee D. Diabetes and cardiovascular disease: the Framingham Study. JAMA 1979;241:2035-8.
4. Stamler J, Vaccaro O, Neaton J, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
5. Wei M, Gaskill S, Haffner S, et al. Effects of diabetes and level of glycaemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998;21:1167-72.
6. Kannel W, D'Agostino R, Wilson P, et al. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990;120:672-6.
7. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.
8. Lusis A. Atherosclerosis. Nature 2000;407:233-41.
9. DeWood M, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
10. Zack P, Ischinger T, Aker U, et al. The occurence of angiographically detected intracoronary thrombus in patients with unstable angina pectoris. Am Heart J 1984;108:1408-12.
11. Lowe C, Drummond M, Third J, et al. Increased plasma fibrinogen and platelet aggregates in type II hyperlipoproteinaemia. Thromb Haemost 1980;42:1503-7.
12. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003;89:601-9.
13. Ernst E, Resch K. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956-63.
14. Fuller J, Keen H, Jarrett R, et al. Haemostatic variables associated with diabetes and its complications. BMJ 1979;2:964-6.
15. Schalkwijk C, Poland D, van Dijk W, et al. Plasma concentration of C-reactive protein is increased in type 1 diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999;42:351-7.
16. Lee P, Jenkins A, Bourke C,et al. Prothrombotic and antithrombotic factors are elevated in patients with type 1 diabetes complicated by microalbuminuria. Diabet Med 1993;10:122-8.
17. Christe M, Fritschi J, Lammle B, et al. Fifteen coagulation factors and fibrinolysis parameters in diabetes mellitus and in patients with vasculopathy. Thromb Haemost 1984;52:138-43.
18. Ford I, Singh T, Kitchen S, et al. Activation of coagulation in diabetes mellitus in relation to the presence of vascular complications. Diabet Med 1991;8:322-9.
19. Ceriello A, Taboga C, Giacomello R, et al. Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes 1994;43:430-2.
20. El Khawand C, Jamart J, Donckier J, et al. Hemostasis variables in type 1 diabetic patients without demonstrable vascular complications. Diabetes Care 1993;16:1137-45.
21. Jensen J, Borsch-Johnsen K, Kofoed-Enevoldsen A, et al. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 1987;30:144-8.
22. Borsch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ 1987;294:1651-4.
23. Krolewski A, Konsinski E, Warram J, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987;59:750-5.
24. Knobl P, Schernthaner C, Schnack C, et al. Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non insulin-dependent) diabetic patients. Diabetologia 1993;36:1045-50.
25. Myrup B, de Maat M, Rossing P, et al. Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Thromb Res 1996;81:485-90.
26. Jensen T, Stender S, Deckert T. Abnormalities in plasmas concentrations of lipoproteins and fibrinogen in type 1 (insulin-dependent) diabetic patients with increased urinary albumin excretion. Diabetologia 1988;31:142-5.
27. Klein R, Hunter S, Jenkins A, et al. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphisms in the DCCT/EDIC cohort. Diabetes Care 2003;26:1439-48.
28. Jones S, Close C, Mattock M,et al. Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria. BMJ 1989;298:487-90.
29. Van Wersch J, Donders S, Westerhuis L, et al. Microalbuminuria in diabetic patients: relationship to lipid, gluco-metabolic, coagulation and fibrinolysis parameters. Eur J Clin Chem Clin Biochem 1991;29:493-8.
30. Jay R, Jones S, Hill D, et al. Blood rheology and cardiovascular risk factors in type 1 diabetes: relationship with microalbuminuria. Diabet Med 1991;8:662-7.
31. Greaves M, Malia R, Goodfellow K, et al. Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study. Diabetologia 1997;40:698-705.
32. Coller B, Frank R, Milton R, et al. Plasma cofactors of platelet function: correlation with diabetic retinopathy and hemoglobins A1a-c. Ann Intern Med 1978;88:311-6.
33. D'Elia J, Weinrauch L, Cleason R, et al. Fibrinogen and factor VII levels improve with glycaemic control in patients with type 1 diabetes mellitus who have microvascular complications. Arch Intern Med 2001;161:98-101.
34. Johansson J, Reichard P, Jensen-Urstad K, et al. Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima-media area, stiffness and diameter in type I diabetes mellitus patients. Eur J Clin Invest 2003;33:472-9.
35. Dubrey S, Reaveley D, Seed M, et al. Risk factors for cardiovascular disease in IDDM. A study of identical twins. Diabetes 1994;43:831-5.
36. Barazzoni R, Zanetti M, Davanzo C, et al. Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: correlation with plasma glucagon concentrations. J Clin Endocrinol Metab 2000;85:3121-5.
37. Crook M, Couchman S, Tutt P. Plasma fibrinogen and its relationship to plasma sialic acid in non-insulin-dependent diabetes mellitus. Blood Coagul Fibrinolysis 1996;7:586-9.
38. Festa A, D'Agostino R, Mykkanen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 1999;19:562-8.
39. Donders S, Lustermans F, van Wersch J. Glycometabolic control, lipids, and coagulation parameters in patients with non-insulin-dependent diabetes mellitus. Int J Clin Lab Res 1993;23:155-9.
40. Avellone C, Di Garbo V, Cordova R, et al. Blood coagulation and fibrinolysis in obese NIDDM patients. Diabetes Res 1994;25:85-92.
41. Collier A, Rumley A, Rumley A, et al. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 1992;41:909-13.
42. Morishita E, Asakura H, Jokaji H, et al. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis 1996;120:7-14.
43. Schmitz A, Ingerslev J. Haemostatic measures in type 2 diabetic patients with microalbuminuria. Diabet Med 1990;7:521-5.
44. Asakawa H, Tokunaga K, Kawakami F. Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy. J Diabetes Complications 2000;14:121-6.
45. Streja D, Cressey P, Rabkin S. Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus. J Diabetes Complications 2003;17:120-7.
46. Missov R, Stolk R, van der Bom J, et al. Plasma fibrinogen in NIDDM: the Rotterdam Study. Diabetes Care 1996;19:157-9.
47. Ceriello A, Mercuri F, Fabbro D, et al. Effect of intensive glycaemic control on fibrinogen plasma concentrations in patients with type II diabetes mellitus. Relation with beta-fibrinogen genotype. Diabetologia 1998;41:1270-3.
48. Lam T, Liu L, Janus E, et al. Fibrinogen, other cardiovascular risk factors and diabetes mellitus in Hong Kong: a community with high prevalence of type 2 diabetes mellitus and impaired glucose tolerance. Diabet Med 2000;17:798-806.
49. Bruno C, Cavallo-Perin P, Bargero C, et al. Association of fibrinogen with glycaemic control and albumin excretion rate in patients with non-insulin dependent diabetes mellitus. Ann Intern Med 1996;125:653-7.
50. Jain A, Cupta H, Narayan S. Hyperfibrinogenaemia in patients of diabetes mellitus in relation to glycaemic control and urinary albumin excretion rate. J Assoc Physicians India 2001;49:225-30.
51. Reid H, Vigilance J, Wright-Pascoe R, et al. The influence of persistent hyperglycaemia on hyperfibrinogenaemia and hyperviscosity in diabetes mellitus. West Indian Med J 2000;49:281-4.
52. Bahru Y, Kesteven P, Alberti K, et al. Decreased plasminogen activator inhibitor-1 activity in newly diagnosed diabetic patients following dietary modification. Diabet Med 1993;10:802-6.
53. Emanuele N, Azad N, Abraira C, et al. Effect of intensive glycaemic control on fibrinogen, lipids, and lipoproteins. Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Arch Intern Med 1998;158:2485-90.
54. Becker A, van der Does F, van Hinsbergh V, et al. Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, Von Willebrand factor and (pro)insulin. Neth J Med 2003;61:129-36.
55. Knobl P, Schernthaner C, Schnack C, et al. Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb Haemost 1994;71:692-7.
56. Fanghanel C, Suva U, Sanchez-Reyes L, et al. Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes. Rev Invest Clin 1998;50:389-94.
57. Jones R, Peterson C. Reduced fibrinogen survival in diabetes mellitus. J Clin Invest 1979;63:485-93.
58. Williams S, Devonny J, Bitensky M. Micropinocytotic ingestion of glycosylated albumin by isolated microvessels. Proc Natl Acad Sci U S A 1981;78:2393-7.
59. Hatton M, Southward S, Ross-Ouellet B, et al. Catabolism of unglycated and naturally glycated forms of rabbit fibrinogen: their interaction with healthy and deendothelialized aorta wall in normal and diabetic rabbits. J Lab Clin Med 1993;121:588-97.
60. Dunn E, Ariens R, de Lange M, et al. Genetics of fibrin clot structure: a twin study. Blood 2004;103:1735-40.
61. De Lange M, Snieder H, Ariens R, et al. The genetics of haemostasis: a twin study. Lancet 2001;357:101-5.
62. Humphries S, Ye S, Talmud P, et al. European Atherosclerosis Research Study: genotype at the fibrinogen locus (G-455-A beta gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe: evidence for gender-genotype-environment interaction. Arterioscler Thromb Vasc Biol 1995;15:96-104.
63. Thomas A, Green F, Humphries S. Association of genetic variation at the beta-fibrinogen gene locus and plasma fibrinogen levels; interaction between allele frequency of the G/A-455 polymorphism, age and smoking. Clin Genet 1996;50:184-90.
64. Thomas A, Lamlum H, Humphries S, et al. Linkage disequilibrium across the fibrinogen locus as shown by five genetic polymorphisms, G/A-455 (HaelII), C/T-148 (HindlII/Alul),T/G+1689 (Avail),and Bcl1 (beta-fibrinogen) and Taql (alpha-fibrinogen), and their detection by PCR. Hum Mutat 1994;3:79-81.
65. Baumann R, Henschen A. Genetic variation in human beta fibrinogen gene promoter influences formation of a specific DNA-protein complex with the interleukin-6 response element. Thromb Haemost 1993;69:961A.abstract.
66. Carter A, Mansfield M, Stickland M, et al. Beta-fibrinogen gene-455 G/A polymorphism and fibrinogen levels. Risk factors for coronary artery disease in subjects with NIDDM. Diabetes Care 1996;19:1265-8.
67. Snowden C, Houlston R, Laker M, et al. Plasma fibrinogen levels and fibrinogen genotype in non-insulin dependent diabetics. Dis Markers 1992;10:159-68.
68. Dalsgaard-Nielsen J, Madsbad S, Hilsted J. Changes in platelet function, blood coagulation and fibrinolysis during insulin-induced hypoglycaemia in juvenile diabetics and normal subjects. Thromb Haemost 1982;47:254-8.
69. De Feo P, Gaisano M, Haymond M. Differential effects of insulin deficiency on albumin and fibrinogen synthesis in humans. J Clin Invest 1991;88:833-40.
70. De Feo P, Volpi E, Lucidi P, et al. Physiological increments in plasma insulin concentrations have selective and different effects on synthesis of hepatic proteins in normal humans. Diabetes 1993;42:995-1002.
71. Barazzoni R, Kiwanuka E, Zanetti M, et al. Insulin acutely increases fibrinogen production in individuals with type 2 diabetes but not in individuals without diabetes. Diabetes 2003;52:1851-6.
72. Tessari P, Iori E, Vettore M, et al. Evidence for acute stimulation of fibrinogen production by glucagon in humans. Diabetes 1997;46:1368-71.
73. Yudkin JS, Panahloo A, Stehouwer C, et al. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects. Diabetologia 2000;43:1099-106.
74. Haffner S, Mykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101:975-80.
75. Reaven G. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
76. Yudkin J, Stehouwer C, Emeis J, et al. C-reactive protein in healthy subjects. Associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.
77. Festa A, D'Agostino R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
78. Pickup J, Crook M. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998;41:1241-8.
79. Pickup J, Mattock M, Chusney C, et al. NIDDM as a disease of the innate immune system, association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;140:1286-92.
80. Pickup J, Day C, Bailey C, et al. Plasma sialic acid in animal models of diabetes mellitus: evidence for modulation of sialic add concentrations by insulin deficiency. Life Sci 1995;57:1383-91.
81. Thompson D, Harrison S, Evans S, et al. Insulin modulation of acute phase protein production in a human hepatoma cell line. Cytokine 1991;3:619-26.
82. Campos S, Baumann H. Insulin is a prominent modulator of the cytokine-stimulated expression of acute phase plasma protein genes. Mol Cell Biol 1992;12:1789-97.
83. Kushner I. Regulation of the acute phase response by cytokines. Perspect Biol Med 1993;36:611-22.
84. Krogh-Madsen R, Plomgaard P, Keller P, et al. Insulin stimulates interleukin-6 and tumor necrosis factor-alpha gene expression in human subcutaneous adipose tissue. Am J Physiol Endocrinol Metab 2004:286:E234-8.
85. Iida K, Shimano H, Kawakami Y, et al. Insulin up-regulates tumor necrosis factor-alpha production in macrophages through an extracellular-regulated kinase-dependent pathway. J Biol Chem 2001;276:32531-7.
86. Morohoshi M, Fujisawa K, Uchimura I, et al. The effect of glucose and advance glycosylation end products on IL-6 production by human monocytes. Ann N Y Acad Sci 1995;748:562-70.
87. Renier G, Clement I, Desfaits A, et al. Direct stimulatory effect of insulin-like growth factor-1 on monocyte and macrophage tumour necrosis factor-α production. Endocrinology 1996;137:4611-8.
88. Soop M, Duxbury H, Agwunobi A, et al. Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans. Am J Physiol Endocrinol Metab 2002:282;E1276-85.
89. Grieninger G, Plant P, Liang J, et al. Hormonal regulation of fibrinogen synthesis in cultured hepatocytes. Ann N Y Acad Sci 1983;408:469-89.
90. Fatah K, Silveira A, Tornvall P, et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996;76:535-40.
91. Blomback B, Carlsson K, Hessel B, et al. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989;997:96-110.
92. Standeven K, Grant P, Carter A, et al. Functional analysis of the fibrinogen A-alpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003;107:2326-30.
93. Ariens R, Philippou H, Nagaswami C, et al. The factor XIII Val34Leu polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000;96:988-95.
94. Mills J, Ariens R, Mansfield M, et al. Altered fibrin clot structure in healthy relatives of patients with premature coronary artery disease. Circulation 2002;106:1938-42.
95. Collet J, Park D, Lesty C, et al. Influence of fibrin network conformation and fibrin fibre diameter on fibrinolysis speed: dynamic and structural analysis approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000;20:1354-61.
96. Gabriel D, Muga K, Boothroyd E. The influence of fibrin fibre mass/length ratio on fibrinolysis. Thromb Haemost 1991;65:904.abstract 737A.
97. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
98. Kohn R, Schnider S. Glycosylation of human collagen in ageing and diabetes mellitus. J Clin Invest 1982;66:1179-81.
99. Monnier V, Cerami A. Non-enzymatic glycosylation and browning in diabetes. Clin Endocrinol Metab 1982;11:431-52.
100. Hammer M, John P, Flynn M, et al. Glycated fibrinogen: a new index of short-term diabetic control. Ann Clin Biochem 1989;26:58-62.
101. Lutjens A, te Velde A, v. d. Veen E, et al. Glycosylation of human fibrinogen In vivo. Diabetologia 1985;28:87-9.
102. Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost 2003;89:409-19.
103. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999;82:259-70.
104. Robinson P, Jury D, Langdon A. The relative clotting activity of glycated and non-glycated forms of fibrinogen. Ann Clin Biochem 1991;28:618-9.
105. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes 1983;32:680-4.
106. Ney K, Pasqua J, Colley K, et al. In vitro preparation of nonenzymatically glycosylated human transferrin, alpha2-macroglobulin, and fibrinogen with preservation of function. Diabetes 1985;34:462-70.
107. Bobbink I, Tekelenburg W, Sixma J, et al. Glycated proteins modulate tissue-plasminogen activator-catalyzed plasminogen activation. Biochem Biophys Res Commun 1997;240:595-601.
108. Lutjens A, Jonkhoff-Slok T, Sandkuijl C, et al. Polymerisation and crosslinking of fibrin monomers in diabetes mellitus. Diabetologia 1988;31:825-30.
109. Jorneskog C, Egberg N, Fagrell B, et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 1996;39:1519-23.
110. Nair C, Azhar A, Wilson J, et al. Studies of fibrin network structure in human plasma, part II: Clinical application: diabetes and antidiabetic drugs. Thromb Res 1991;64:477-85.
111. Gabriel D, Muga K, Boothroyd E. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992;267:24259-63.
112. Carr M, Alving B. Effect of fibrin structure on plasmin mediated dissolution of plasma clots. Blood Coagul Fibrinolysis 1995;6:567-73.
113. Williams S, Fatah K, Ivert T, et al. The effect of acetyl salicylic acid on fibrin gel lysis by tissue plasminogen activator. Blood Coagul Fibrinolysis 1995;6:718-25.
114. Jorneskog G, Hansson L, Wallen N, et al. Increased plasma fibrin gel porosity in patients with type 1 diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost 2003;1:1195-201.
115. Wilf J, Gladner J, Ap M. Acceleration of fibrin gel formation by unrelated proteins. Thromb Res 1985;37:681-8.
116. Torbet J. Fibrin assembly in human plasma and fibrinogen/albumin mixtures. Biochemistry 1986;25:5309-14.
117. Standeven K, Ariens R, Whitaker P, et al. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 2002;51:189-97.
118. UKPDS group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.